Home > Formulary : Adult > Recent Decisions > 2013 >
Decisions 15th October 2013
Recent JFG Decisions
At the meeting on the 15th October 2013 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Lisdexamfetamine
- Approved for inclusion, TLS Red, second line option for those patients who have had an inadequate response to methylamphetamine
Levobupivacaine
- Approved for inclusion onto the formulary, TLS Red
Dexmedetomidine
- Approved for inclusion to the formulary for patients who are failing to wean from invasive ventilation with traditional management due to agitation
Ingenol
- Approved for inclusion to the Joint Formulary on the grounds of efficacy, cost, and ease of administration. TLS Green. Solaraze® to remain on formulary.
Ozurdex®
- Approved for inclusion to the Joint Formulary.
Rejected
Linaclotide
- The decision to reject the original application made at the meeting on the 10th September was upheld.
Awaiting Financial agreement
Ferinject®
- Approved for inclusion to the Joint Formulary on the grounds of efficacy, cost, and reduction in administration time. TLS Red. Will be included in the formulary once there is confirmation of financial acceptance from the acute trusts.
Shared Care Protocols
Rifaximin
- The new SCP NOT accepted. The JFG requested to await the NICE Technology appraisal due in January 2014
Rivaroxaban for Pulmonary Embolism
- New SCP accepted, amber 1 month.
Methotrexate for IBD
- Currently amber without a SCP. The SCP needs to be sent around to the GPs for comment, and will be brought back to the next meeting.